ROR1 and cancer: Head-to-head comparison in a panel of ROR1 positive cancer cell lines demonstrated that the ROR1 BiTE containing an scFv directed against the Fr domain yielded consistently superior and reproducible cytotoxicity compared with BiTEs targeting the Ig domain (Fig. 1H).